ABC

Triple-A Rated J&J’s Opioid Liabilities Likely More Than Priced In

by

  Image Source: J&J Shares of J&J have settled into the high-$120s at the time of this writing, well below our ~$150 fair value estimate. We’re going to stick with J&J in both the Dividend Growth Newsletter portfolio and Best Ideas Newsletter portfolio at this time. By Callum Turcan and Brian Nelson, CFA On August 26, an Oklahoma judge ruled that Johnson & Johnson (JNJ) had to pay $572 million to the state over its role in the opioid crisis in America. In particular, District Judge Thad Balkman noted that “Johnson & Johnson’s misleading marketing and promotion of opioids created a nuisance” that compromised the health of thousands in Oklahoma. Johnson & Johnson and its Janssen subsidiary will contest the … Read more

VBI 9-Rated AmerisourceBergen Now On Our Radar

by

Let’s take a look at VBI 9-rated stock AmerisourceBergen, a pharmaceutical sourcing and distribution company that yields 2% as of this writing. We like AmerisourceBergen’s dividend growth story, strong free cash flow generation, guidance raise, and relatively low net debt load. We’ll also cover AmerisourceBergen’s downside risks as well as its upside potential. Shares appear undervalued as things stand today, with ABC trading below the low end of our fair value estimate range. By Callum Turcan Pharmaceutical sourcing and distribution company AmerisourceBergen (ABC) just popped up on our radar; its fundamentals are rock-solid and its technical readings indicate Wall Street is starting to take notice. The company just registered a 9 on the Valuentum Buying Index. This American healthcare company has consistently generated … Read more

Our Reports on Stocks in the Healthcare Products Distributors Industry

by

Images Source: Express Scripts Structure of the Healthcare Products/Distributors Industry The healthcare distributors industry is made up of wholesale medical equipment products distributors, serving the dental, medical and animal health markets, and wholesale drug providers, which distribute pharmaceuticals, medical products/services, and other healthcare technologies. Both sub-spaces are highly competitive and continue to experience growth as a result of the aging population, increased healthcare awareness, and the proliferation of medical technology and testing. Participants face pricing pressure from both customers and suppliers as a result of competition. We’re neutral on the group. We have dropped coverage of the Healthcare Products/Distributors Industry.

Markets Swooning, Expect Extreme Volatility, Finger on Put-Option Trigger

by

Image shown: We notified members December 26 that we had  moved  the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio to a “fully invested” position, from a 30% and 20% cash “weighting” at the high end of the range, respectively.  — No change to simulated newsletter portfolios…at this time.  — Hi everyone, — Hope you’re navigating these tumultuous markets well.   — If you recall, during the holiday season last year, we had moved the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio to “fully invested.” See image above (point of the arrow). Because many members were traveling and out of the office, not all were able to read the notification until a week or two after. They were … Read more

ATTN: Advisors and Planners — Disruption Is Looming

by

“With the commoditization of investment advice and intense competition from robos and other more cost-efficient solutions, growth-minded advisors want to create bespoke experiences for clients.” — WealthManagement.com By Brian Nelson, CFA Hi Valuentum members, colleagues and friends, Valuentum has a large subscriber base and is one of the most successful paid subscription financial information websites launched this decade. Over the past eight years or so, individuals, financial advisors and money managers from all over the world have subscribed to our services. We pride ourselves on independence and transparency, and we’re a champion of the investor. Today, I’d like to talk directly to our financial advisor, financial planner, and professional money-manager members. You probably already heard the news yesterday: Charles Schwab, which handles … Read more

DG Newsletter Alert, Markets on a Roll! New Highs Coming?

by

Image shown: We notified members December 26 that we had moved the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio to a “fully invested” position, from a 30% and 20% cash “weighting” at the high end of the range, respectively. It doesn’t look like the timing could have been much better.  Changes to Dividend Growth Newsletter portfolio Removing Novartis (NVS) -3.5%-5.5% Adding Health Care Select Sector SPDR Fund (XLV) +3.5%-5.5% By Brian Nelson, CFA The back half of 2018 was among the most exciting in Valuentum’s history. For one, we might have made one of our best “market-direction” calls since inception in practically calling the near-term bottom December 26. In hindsight, it’s clear the market had overreacted, but at the time, going to “fully … Read more

Valuentum’s Stock and Data Screens and Screeners

by

Let’s go over where to find Valuentum’s stock and data screens and screeners. We believe our stock screeners are among the most robust when it comes to providing forward-looking data, and our data comes straight from our enterprise discounted cash flow models that we use to derive a company’s fair value estimate. By The Valuentum Team In late 2017, we made the decision to transition to providing an updated Excel download each week to members in order to allow them to facilitate any combination of screening criteria they want with respect to our vast amounts of data, whether it be the Valuentum Buying Index, the Dividend Cushion ratio or other. What we’ve found out the past 15 months or so … Read more

Kraft-Heinz Blows Up, More Updates!

by

Image shown: The rating history of Kraft-Heinz (KHC). Valuentum members were warned in advance of this pricey equity in 2016/2017, and the VBI rating never advanced past 5 since then after registering a 1, the worst rating, on two separate occasions. Dear members, I wanted to first of all welcome our new members. There have been a lot of new ones during the past few weeks. Thank you. The buzz might be coming from the new book launch, Value Trap. If you haven’t read the book yet, please do so here. Members can get the pdf digital download today at 25% off. For new members, reading this book is simply par for the course to get a feel for how we look at … Read more

Consider Selling Discipline = Systematic, Forward-looking, Repeatable

by

Image shown: An illustration of Valuentum’s call on Kinder Morgan during 2015. You can read about this in more detail in the Preface of Value Trap: Theory of Universal Valuation. For a consider-selling discipline to be successful, it must be systematic, forward-looking and repeatable. The Valuentum process worked equally well with General Electric during 2017 (image later in note). No changes to simulated newsletter portfolios. By Brian Nelson, CFA Good morning everyone! The markets took a shellacking yesterday with the Dow Jones Industrial Average (DIA) falling over 300 points during the trading session January 22. Had there not been a near-100 point leap in the Dow during the past few minutes of trading, the fallout may have been worse. Most are … Read more

Conference Call Coming Soon, Catch Up This Weekend

by

Image shown: The markets continue to rally significantly since the near-term bottom in December. Here’s the email we sent to members December 26.  No changes to simulated Best Ideas Newsletter portfolio and simulated Dividend Growth Newsletter portfolio (contact us if you missed the latest notification regarding the simulated High Yield Dividend Newsletter portfolio). This article was sent to members via email January 19. That email can be accessed at the link that follows this article. Conference Call Monday, January 28, 11amET/10amCT. We’ll talk about website navigation, how to use the stock and dividend reports, and dig deep into our capital-appreciation and dividend growth methodology. Details to follow, but add this date/time to your calendar. Read what some of our members have … Read more